Key result
None of the 28 studied naturally occurring ACE2 missense variants significantly altered the receptor's intracellular trafficking or subcellular targeting to the plasma membrane compared to wild type ACE2.
Why the study?
Genetic variability in ACE2 has been suggested to contribute to variable COVID-19 clinical manifestations, but the effects of naturally occurring missense variants on ACE2 protein folding, trafficking, and subcellular targeting have not been established.
Naturally occurring missense variants in ACE2 do not appear to alter its subcellular trafficking or targeting to the plasma membrane.
ACE2 missense variants do not disrupt trafficking in this model; leaves open effects on other functions or human relevance.
BACKGROUND: Human angiotensin-converting enzyme 2 (ACE2), a type I transmembrane receptor physiologically acting as a carboxypeptidase enzyme within the renin-angiotensin system (RAS), is a critical mediator of infection by several severe acute respiratory syndrome (SARS) corona viruses. For instance, it has been demonstrated that ACE2 is the primary receptor for the SARS-CoV-2 entry to many human cells through binding to the viral spike S protein. Consequently, genetic variability in ACE2 gene has been suggested to contribute to the variable clinical manifestations in COVID-19. Many of those genetic variations result in missense variants within the amino acid sequence of ACE2. The potential effects of those variations on binding to the spike protein have been speculated and, in some cases, demonstrated experimentally. However, their effects on ACE2 protein folding, trafficking and subcellular targeting have not been established. RESULTS: In this study we aimed to examine the potential effects of 28 missense variants (V801G, D785N, R768W, I753T, L731F, L731I, I727V, N720D, R710H, R708W, S692P, E668K, V658I, N638S, A627V, F592L, G575V, A501T, I468V, M383I, G173S, N159S, N149S, D38E, N33D, K26R, I21T, and S19P) distributed across the ACE2 receptor domains on its subcellular trafficking and targeting through combinatorial approach involving in silico analysis and experimental subcellular localization analysis. Our data show that none of the studied missense variants (including 3 variants predicted to be deleterious R768W, G575V, and G173S) has a significant effect on ACE2 intracellular trafficking and subcellular targeting to the plasma membrane. CONCLUSION: Although the selected missense variants display no significant change in ACE2 trafficking and subcellular localization, this does not rule out their effect on viral susceptibility and severity. Further studies are required to investigate the effect of ACE2 variants on its expression, binding, and internalization which might explain the variable clinical manifestations associated with the infection.
No takes yet. Share an insight, caveat, or question.
Badawi et al. (2022) studied SARS-CoV-2 / COVID-19. ACE2 missense variants vs. Wild type ACE2 was evaluated on Subcellular localization and trafficking to the plasma membrane. None of the 28 studied naturally occurring ACE2 missense variants significantly altered the receptor's intracellular trafficking or subcellular targeting to the plasma membrane compared to wild type ACE2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: